Study points to a strategy for inhibiting hyper-progression of melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Opinion | ‘It Is a Horrifying Prospect’: What We Heard This Year

In place of our usual “What We Heard This Week” feature, and as part of our year-end wrap-ups, we’ve selected some of the best quotes

January 1, 2024

Gameto says first baby born using new stem-cell tech

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Some exciting

December 17, 2024

Researchers publish early results with new interleukin-targeting antibody – Pharmaceutical Technology

The antibody, which has been called Ab-IPL-IL-17, targets a sequence in both IL-17A and IL-17F. It has demonstrated positive results for rheumatoid arthritis treatment in

August 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.